Pridopidine in ALS Phase 3
Prilenia and Ferrer plan a pivotal Phase 3 study of pridopidine in Amyotrophic Lateral Sclerosis (ALS) to confirm Phase 2 gains, with enrollment in early 2026. Pridopidine is an oral sigma-1 receptor agonist that lab data show can reduce stress in nerve cells and support their survival, offering hope for a new ALS therapy.
Press Release#Amyotrophic Lateral Sclerosis (ALS)#Motor Neurone Disease (MND)#Clinical Trial#Pridopidine